Close Menu
April 27, 2020
Sponsored by
BC Platforms

Bioinformatics Innovation and COVID-19: An Integrated Platform to Harness Real-Time Research Insights in the Clinic

GenomeWebinar

This webinar will discuss how to leverage an integrated platform for discovery and research in order to accelerate the translation of insights into clinical understanding, highlighting this process in the context of the fight against the COVID-19 pandemic.

Professor James Batchelor, Director of the Clinical Informatics Research Unit at the University of Southampton, will describe the ways his team adapted an existing framework, in collaboration with BC Platforms, to understand multiple aspects and parameters relating to COVID-19 patient treatment in the NHS.

In the context of COVID-19, which has already proven to be a significant burden on healthcare systems worldwide, hospitals are looking to apply and integrate more technology-based solutions to share data and insights in order to help solve this global challenge. The University Hospital of Southampton (UHS) and the University of Southampton has acted quickly to address this need and use bioinformatics innovation, with the support of BC Platforms’ underlying system BC|INSIGHT, to integrate, stage and analyze real time clinical data in order to understand high level clinical presentation risk stratification and monitor the progression in COVID-19 patients.

This webinar will highlight insights gained while using a system to coordinate research studies in a single platform, and how this framework can be applied to the challenges associated with the burden of COVID-19.

Sponsored by

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.